NCT02934568: Ribociclib (LEE011) Rollover Study for Continued Access

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patient must be currently enrolled in an eligible Novartis-sponsored study & receiving clinical benefit from ribociclib (LEE011) as single agent or in combination with another investigational treatment

Comments are closed.

Up ↑